Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Sanjiv Patel, President and CEO of Relay Therapeutics, Inc. (NASDAQ:RLAY), a $656 million market cap biotech company currently trading at $3.96, recently executed notable stock transactions as ...

Genescience Pharmaceuticals Co. Ltd. has prepared and tested new fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...